Joel Greenblatt's FOLD Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 139,551 shares of Amicus Therapeutics, Inc. (FOLD) worth $1.99 M, representing 0.01% of the portfolio. First purchased in 2017-Q2, this medium-term investment has been held for 18 quarters.
Based on 13F filings, Joel Greenblatt has maintained a strategic position in FOLD, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 82,546 shares. Largest reduction occurred in Q3 2017, reducing 30,628 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Amicus Therapeutics (FOLD) Holding Value Over Time
Track share changes against reported price movement
Quarterly Amicus Therapeutics (FOLD) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +1,028 | Add 0.74% | 139,551 | $14.24 |
| Q3 2025 | +1,987 | Add 1.46% | 138,523 | $7.88 |
| Q2 2025 | +82,546 | Add 152.89% | 136,536 | $5.73 |
| Q1 2025 | +53,990 | New Buy | 53,990 | $8.16 |
| Q4 2023 | -10,606 | Sold Out | 0 | $0.00 |
| Q3 2023 | -5,652 | Reduce 34.76% | 10,606 | $12.16 |
| Q2 2023 | -20,242 | Reduce 55.46% | 16,258 | $12.56 |
| Q1 2023 | +18,466 | Add 102.40% | 36,500 | $11.09 |
| Q4 2022 | +18,034 | New Buy | 18,034 | $12.21 |
| Q3 2022 | -11,561 | Sold Out | 0 | $0.00 |
| Q2 2022 | +11,561 | New Buy | 11,561 | $10.73 |
| Q1 2022 | -26,356 | Sold Out | 0 | $0.00 |
| Q4 2021 | +9,537 | Add 56.70% | 26,356 | $11.53 |
| Q3 2021 | +16,819 | New Buy | 16,819 | $9.57 |
| Q2 2019 | -11,047 | Sold Out | 0 | $0.00 |
| Q1 2019 | +11,047 | New Buy | 11,047 | $13.58 |
| Q3 2017 | -30,628 | Sold Out | 0 | $0.00 |
| Q2 2017 | +30,628 | New Buy | 30,628 | $10.06 |
Joel Greenblatt's Amicus Therapeutics Investment FAQs
Joel Greenblatt first purchased Amicus Therapeutics, Inc. (FOLD) in Q2 2017, acquiring 30,628 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Amicus Therapeutics, Inc. (FOLD) for 18 quarters since Q2 2017.
Joel Greenblatt's largest addition to Amicus Therapeutics, Inc. (FOLD) was in Q2 2025, adding 136,536 shares worth $782,351.
According to the latest 13F filing for Q4 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 139,551 shares of Amicus Therapeutics, Inc. (FOLD), valued at approximately $1.99 M.
As of the Q4 2025 filing, Amicus Therapeutics, Inc. (FOLD) represents approximately 0.01% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in Amicus Therapeutics, Inc. (FOLD) was 139,551 shares, as reported at the end of Q4 2025.